{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T14:37:55Z","timestamp":1771511875306,"version":"3.50.1"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Univar Solutions BV"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Pharmacol"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s00228-025-03953-0","type":"journal-article","created":{"date-parts":[[2026,1,7]],"date-time":"2026-01-07T08:10:42Z","timestamp":1767773442000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Further elucidation on the effect of food on the pharmacokinetics of trientine"],"prefix":"10.1007","volume":"82","author":[{"given":"Karl Heinz","family":"Weiss","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carlot","family":"Kruse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khalid","family":"Abd-Elaziz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"van der Horst","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"ChauHwei","family":"Fu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena","family":"Aliane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Jaap","family":"Scherpbier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireille","family":"Gerrits","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Dogterom","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,7]]},"reference":[{"key":"3953_CR1","doi-asserted-by":"publisher","unstructured":"Schilsky ML, Roberts EA, Bronstein JM et al (2022) A multidisciplinary approach to the diagnosis and management of Wilson disease: 2022 practice guidance on Wilson disease from the American Association for the Study of Liver Diseases. Hepatol n\/a. https:\/\/doi.org\/10.1002\/hep.32801","DOI":"10.1002\/hep.32801"},{"key":"3953_CR2","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.jhep.2024.11.007","volume":"82","author":"P Socha","year":"2025","unstructured":"Socha P, Ja\u0144czyk W, Zanetto A et al (2025) EASL-ERN clinical practice guidelines on wilson\u2019s disease. J Hepatol 82:690\u2013728. https:\/\/doi.org\/10.1016\/j.jhep.2024.11.007","journal-title":"J Hepatol"},{"key":"3953_CR3","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1248\/yakushi1947.110.10_759","volume":"110","author":"M Kobayashi","year":"1990","unstructured":"Kobayashi M, Sugawara M, Saitoh H et al (1990) [Intestinal absorption and urinary excretion of Triethylenetetramine for wilson\u2019s disease in rat]. Yakugaku Zasshi 110:759\u2013763. https:\/\/doi.org\/10.1248\/yakushi1947.110.10_759","journal-title":"Yakugaku Zasshi"},{"key":"3953_CR4","first-page":"179","volume":"49","author":"S Takeda","year":"1995","unstructured":"Takeda S, Ono E, Matsuzaki Y et al (1995) Metabolic fate of Triethylenetetramine dihydrochloride (trientine hydrochloride, TJA-250). 3. Bioavailability of TJA-250 in rats after single administration. Pharmacometrics 49:179\u2013186","journal-title":"Pharmacometrics"},{"key":"3953_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jconrel.2006.12.016","volume":"118","author":"S Sakuma","year":"2007","unstructured":"Sakuma S, Tanno FK, Masaoka Y et al (2007) Effect of administration site in the Gastrointestinal tract on bioavailability of poorly absorbed drugs taken after a meal. J Controlled Release 118:59\u201364. https:\/\/doi.org\/10.1016\/j.jconrel.2006.12.016","journal-title":"J Controlled Release"},{"key":"3953_CR6","doi-asserted-by":"publisher","first-page":"5341","DOI":"10.1002\/jps.21382","volume":"97","author":"FK Tanno","year":"2008","unstructured":"Tanno FK, Sakuma S, Masaoka Y et al (2008) Site-specific drug delivery to the middle-to-lower region of the small intestine reduces food\u2013drug interactions that are responsible for low drug absorption in the fed state. J Pharm Sci 97:5341\u20135353. https:\/\/doi.org\/10.1002\/jps.21382","journal-title":"J Pharm Sci"},{"key":"3953_CR7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.jhazmat.2019.03.085","volume":"373","author":"Z Li","year":"2019","unstructured":"Li Z, Chang P-H, Jiang W-T (2019) Mechanisms of Cu2+, Triethylenetetramine (TETA), and Cu-TETA sorption on rectorite and its use for metal removal via metal-TETA complexation. J Hazard Mater 373:187\u2013196. https:\/\/doi.org\/10.1016\/j.jhazmat.2019.03.085","journal-title":"J Hazard Mater"},{"key":"3953_CR8","doi-asserted-by":"publisher","first-page":"38","DOI":"10.3390\/medsci10030038","volume":"10","author":"K Zahedi","year":"2022","unstructured":"Zahedi K, Barone S, Soleimani M (2022) Polyamines and their metabolism: from the maintenance of physiological homeostasis to the mediation of disease. Med Sci 10:38. https:\/\/doi.org\/10.3390\/medsci10030038","journal-title":"Med Sci"},{"key":"3953_CR9","doi-asserted-by":"crossref","unstructured":"Rupp C, Weiss KH (2019) Chap. 35 - Oral chelator treatment of Wilson disease: trientine. In: Kerkar N, Roberts EA (eds) Clinical and translational perspectives on WILSON DISEASE. Academic Press, pp 365\u2013372","DOI":"10.1016\/B978-0-12-810532-0.00035-5"},{"key":"3953_CR10","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1158\/1535-7163.MCT-10-0523","volume":"9","author":"J Lu","year":"2010","unstructured":"Lu J (2010) Triethylenetetramine Pharmacology and its clinical applications. Mol Cancer Ther 9:2458\u20132467. https:\/\/doi.org\/10.1158\/1535-7163.MCT-10-0523","journal-title":"Mol Cancer Ther"},{"key":"3953_CR11","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1007\/s13318-021-00704-1","volume":"46","author":"KH Weiss","year":"2021","unstructured":"Weiss KH, Thompson C, Dogterom P et al (2021) Comparison of the Pharmacokinetic profiles of trientine tetrahydrochloride and trientine dihydrochloride in healthy subjects. Eur J Drug Metab Pharmacokinet 46:665\u2013675. https:\/\/doi.org\/10.1007\/s13318-021-00704-1","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"3953_CR12","unstructured":"European Medicines Agency (2019) Cufence summary of product characteristics. https:\/\/www.ema.eu\/en\/documents\/productinformation\/cufence-epar-product-information_en.pdf"},{"key":"3953_CR13","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1007\/s00228-018-2424-6","volume":"74","author":"J Pfeiffenberger","year":"2018","unstructured":"Pfeiffenberger J, Kruse C, Mutch P et al (2018) The steady state pharmacokinetics of trientine in Wilson disease patients. Eur J Clin Pharmacol 74:731\u2013736. https:\/\/doi.org\/10.1007\/s00228-018-2424-6","journal-title":"Eur J Clin Pharmacol"},{"key":"3953_CR14","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1177\/0091270009349379","volume":"50","author":"J Lu","year":"2010","unstructured":"Lu J, Poppitt SD, Othman AA et al (2010) Pharmacokinetics, pharmacodynamics, and metabolism of Triethylenetetramine in healthy human participants: an open-label trial. J Clin Pharmacol 50:647\u2013658. https:\/\/doi.org\/10.1177\/0091270009349379","journal-title":"J Clin Pharmacol"},{"key":"3953_CR15","unstructured":"Investigation of bioequivalence - Scientific guideline. In: Eur. Med. EMA, Agency (2018) https:\/\/www.ema.europa.eu\/en\/investigation-bioequivalence-scientific-guideline . Accessed 5 Jun 2023"},{"key":"3953_CR16","unstructured":"Handbook Good laboratory practice (2nd edition). In: GOV.UK. https:\/\/www.gov.uk\/research-for-development-outputs\/handbook-good-laboratory-practice-2nd-edition. Accessed 16 May 2023"},{"key":"3953_CR17","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1002\/jimd.12430","volume":"44","author":"E Jacquelet","year":"2021","unstructured":"Jacquelet E, Poujois A, Pheulpin M-C et al (2021) Adherence to treatment, a challenge even in treatable metabolic rare diseases: A cross sectional study of wilson\u2019s disease. J Inherit Metab Dis 44:1481\u20131488. https:\/\/doi.org\/10.1002\/jimd.12430","journal-title":"J Inherit Metab Dis"},{"key":"3953_CR18","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13643-019-1014-8","volume":"8","author":"A Gast","year":"2019","unstructured":"Gast A, Mathes T (2019) Medication adherence influencing factors\u2014an (updated) overview of systematic reviews. Syst Rev 8:112. https:\/\/doi.org\/10.1186\/s13643-019-1014-8","journal-title":"Syst Rev"},{"key":"3953_CR19","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.3390\/pharmaceutics13071100","volume":"13","author":"K Kvarnstr\u00f6m","year":"2021","unstructured":"Kvarnstr\u00f6m K, Westerholm A, Airaksinen M, Liira H (2021) Factors contributing to medication adherence in patients with a chronic condition: A scoping review of qualitative research. Pharmaceutics 13:1100. https:\/\/doi.org\/10.3390\/pharmaceutics13071100","journal-title":"Pharmaceutics"},{"key":"3953_CR20","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s12883-019-1502-4","volume":"19","author":"W Mase\u0142bas","year":"2019","unstructured":"Mase\u0142bas W, Cz\u0142onkowska A, Litwin T, Niewada M (2019) Persistence with treatment for Wilson disease: a retrospective study. BMC Neurol 19:278. https:\/\/doi.org\/10.1186\/s12883-019-1502-4","journal-title":"BMC Neurol"},{"key":"3953_CR21","first-page":"95","volume":"10","author":"A Shuna","year":"1983","unstructured":"Shuna A, Osman MA, Patel RB, Welling PG, Sundstrom WR (1983) Influence of food on the bioavailability of penicillamine. J Rheumatol 10:95\u201397","journal-title":"J Rheumatol"},{"key":"3953_CR22","doi-asserted-by":"publisher","first-page":"84","DOI":"10.33590\/emj\/FUMO2589","volume":"9","author":"F Di Dato","year":"2024","unstructured":"Di Dato F, Hedera P (2024) Zinc for wilson\u2019s disease: what we know and what we don\u2019t know. EMJ 9:84\u201395. https:\/\/doi.org\/10.33590\/emj\/FUMO2589","journal-title":"EMJ"}],"container-title":["European Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00228-025-03953-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00228-025-03953-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T13:39:21Z","timestamp":1771508361000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00228-025-03953-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["3953"],"URL":"https:\/\/doi.org\/10.1007\/s00228-025-03953-0","relation":{},"ISSN":["0031-6970","1432-1041"],"issn-type":[{"value":"0031-6970","type":"print"},{"value":"1432-1041","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"21 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"K.H. Weiss advises for Univar Solutions BV, Vivet Therapeutics, Alexion, Orphalan, Ultragenyx, Pfizer, AbbVie, Bayer and is on the speakers bureau of Alexion, Orphalan and Falk and received travel support from Alexion. For the remaining authors, no conflict of interests were declared.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"23"}}